LongBio Pharma
LongBio Pharma (Suzhou/Shanghai, founded 2020) is a Chinese clinical-stage biopharmaceutical company focused on the in-house discovery and development of innovative antibody and fusion-protein therapeutics for allergic, autoimmune, and complement-mediated diseases. Its lead programs include the anti-IgE antibody LP-003 for chronic spontaneous urticaria and asthma. Co-founded by Dr. Bill Nai-chau Sun (co-founder of Tanox and co-inventor of Omalizumab/Xolair), LongBio raised a Series B2 round led by Qiming Venture Partners and listed on the Hong Kong Stock Exchange (01779.HK) in June 2026. It is a pharmaceutical drug developer with no public developer or API surface; this profile was surfaced as a Qiming portfolio company and completed an enrichment pass.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
LongBio Pharma is tracked in the API Evangelist network. This page is the human-readable profile that sits on top of the machine-readable index we maintain at apis.io.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — LongBio Pharma scores 5.7/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
Resources
Every other property we hold for LongBio Pharma — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Company 2
The organization behind the API
LongBio Pharma is in the network as a tracked entity. We haven't yet indexed a public API surface for it — when one is published, the artifacts, score, and agent-readiness read will appear here automatically. The source repository is where that profile is built.
← All providers · Data indexed from github.com/api-evangelist/longbio · machine-readable index on apis.io